The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?

References

• Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107–19
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodriques Pereira JR, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–6
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007;12:1–5
   PubMedGoogle Scholar
• Uhm JE, Park BB, Ahn MJ, et al. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol 2009;4:1136–43
   PubMed Web of Science ®Google Scholar
• Drobnienė M, Cicėnienė A, Zelvienė TP, et al. Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy. Medicina 2011;47:520–5
   PubMedGoogle Scholar
• Mazzoni F, Rotella V, Pratesi N, et al. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. Tumori 2011;97:160–5
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Linardou H, Kosmidis P, et al. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 2011;22:545–52
   PubMed Web of Science ®Google Scholar
• Faehling M, Eckert R, Kuom S, et al. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 2010;78:249–58
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003;17:23–8.
   PubMedGoogle Scholar
• Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. The Oncologist 2007;12:610–21
   PubMed Web of Science ®Google Scholar
• Thatcher N, Nicolson M, Groves RW, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. The Oncologist 2009;14:840–7
   PubMed Web of Science ®Google Scholar
• Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599–606
   PubMedGoogle Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–65
   PubMed Web of Science ®Google Scholar
• Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème. Radiol Oncol 2008;42:2152–4
   Google Scholar
• Tsutani K, Igarashi A, Shiroiwa T. Pharmacoeconomics of molecular target drugs in Japan. Nihon Rinsho. 2010;68:1923–8
   PubMedGoogle Scholar
• Kobayashi T, Koizumi T, Agatsuma T, et al. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012;69:1241–6
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Hotta K, Kiura K, et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 2010;5:99–104
   PubMed Web of Science ®Google Scholar
• Pander J, Guchelaar HJ, Gelderblom H. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: optimizing the magic bullet. Curr Opin Mol Ther 2010;12:654–61
   PubMed Web of Science ®Google Scholar
• John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009;28:14–23
   PubMed Web of Science ®Google Scholar
• Sasaki H, Okuda K, Shimizu S, et al. EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol 2009;135:313–18
   PubMed Web of Science ®Google Scholar
• Liu W, Wu X, Zhang W, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 2007;13:6788–95
   PubMed Web of Science ®Google Scholar
• Binder D, Buckendahl AC, Hübner RH, et al. Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Med Oncol 2012;29:193–8
   PubMed Web of Science ®Google Scholar